|
Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute’s Vanguard Study
In this original research article in Cancer Epidemiology, Biomarkers & Prevention, NCI authors explain the evaluation framework they created to select multi-cancer detection (MCD) assays for the Vanguard Study.
Read the article.
|
 No-Cost Extension Functionality in eRA
NIH has re-enabled the No-Cost Extension functionality within eRA Commons. Grant recipients may resume initiating first no-cost extensions in eRA Commons, in accordance with the NIH Grants Policy. Requests that were previously submitted via the prior approval module will not be reviewed, and recipients will need to initiate the first no-cost extension within the Status module by using the Extension action.
NOT-OD-25-142
|
Implementation Guidance for Foreign Subawards for Active Projects
NIH will not issue awards to domestic or foreign entities (new, renewal, or non-competing continuation) that include a subaward to a foreign entity. This Guide Notice updates the policy concerning existing projects and submitted applications. This change is to ensure NIH can transparently and reliably report on each dollar spent on foreign collaborations.
NOT-OD-25-130
NCI Full Year Funding Policy for RPG Awards
NCI established policies for full year, fiscal year (FY) 2025 policies considering the budget outlook for FY2026.
Read more.
|
|
Precision Cancer Immunotherapy for Pancreatic Cancer
Wednesday, September 10
3:00-4:00 p.m. ET
Advance registration required
Dr. Balachandran will give a talk on precision cancer immunotherapy for pancreatic cancer as part of the NCI DCP Immunology Interest Group Seminar Series.
Speaker
Vinod Balachandran, M.D., FACS
Surgeon-Scientist and Director, The Olayan Center for Cancer Vaccines
Hutham S. Olayan and Robert F. Raucci Chair
Associate Member, Immuno-Oncology Program, Sloan Kettering Institute
Associate Attending Surgeon, Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center
|
|
|
Forecast to Publish Notice of Funding Opportunities (NOFOs) |
|
NCI Community Oncology Research Program (NCORP)
NIH has posted the Forecast to Publish three Notices of Funding Opportunities (NOFOs) for the NCI Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial results through accrual in a variety of community settings.
NOT-CA-25-042: NCORP Research Bases (UG1 Clinical Trials Required)
NOT-CA-25-043: NCORP Community Sites (UG1 Clinical Trials Not Allowed)
NOT-CA-25-044: NCORP Academic Community Sites (UG1 Clinical Trials Not Allowed)
Estimated Application Due Date: November 14, 2025
|
|
|
The NCI Cancer Prevention Fellowship Program Application Period Closes Next Month!
NCI PREVENT Cancer Program – Research Support Opportunity in Cancer Prevention & Interception
|
2025 Deadline: November 3, 2025
For more information on Program support, types of supported projects, and the application, visit the PREVENT web page.
|
|
 |
In case you missed it:
Read more DCP Updates.
Follow DCP's LinkedIn page.
See all Meetings and Events on the DCP Website.
Do you forward DCP Updates to others?
Encourage them to subscribe.
|
|
|
|
